The fifteenth edition of the Diamonds of Slovak Business Awards showed a dozen companies characterized by rapid growth, turnover in millions of euros, and future potential. We ranked 3rd in the Eastern Slovakia category. Why did Forbes and Enterprise Investors set up this competition? What made us one of the award-winning companies? What plans do we have in the company for the future?
For the 15th time, the Diamonds of Slovak Business Awards have recognized the most dynamically growing SMEs in five categories. It is the only ranking in our country that has long been mapping companies with no foreign assets.
The aim is to show that the business sector in Slovakia is not just about multinational corporations with Bratislava offices. Even smaller companies, which are not covered in the media on a daily basis, are an important element of our country’s economy – they create jobs, contribute to regional development, and create value.
And what criteria does a company have to meet for a chance to be included in the ranking compiled by Enterprise Investors, Forbes magazine, and other partners? The company has at least three recent years of continuous operation, annual sales of EUR €5 – 75 million over the same period, profitability since at least 2020, and no foreign assets.
Co-founders of our company, Martin and Adam Guniš (in the middle), received the Diamonds of Slovak Business award.
When Martin Guniš founded the company in 2016, he didn’t know how fast we would grow in the next five years. Collagen was the first product we started producing. At that time, it was not so popular yet. Now we process more than 150 tonnes of collagen on our lines every year, and demand is still growing.
Collagen was just the beginning. We have added more nutritional supplements gradually. Currently, we have more than 300 ingredients in stock. This growth led to the relocation of production to larger premises several times. We currently have more than 80 people working in our company in 2,000 square meters. In the spring of 2024, our premises are expected to double in size.
We exceeded 2 million in sales in 2019. In 2022, it was over EUR 11 million. Although we specialize in powder, tablet, and capsule nutritional supplements, we would like to eventually launch generic drug production for the pharmaceutical industry as well.